NCT06960395 2026-04-13
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Vir Biotechnology, Inc.
Phase 1 Recruiting
Vir Biotechnology, Inc.
Kumquat Biosciences Inc.
University of Kansas Medical Center